PAT-048

• Description:

  PAT-048 is a potent, selective and orally active autotaxin inhibitor, inhibits IL-6 mRNA expression, but shows no effect on autotaxin protein and pulmonary lysophosphatidic acid (LPA) production in lung fibrosis model. PAT-048 shows an IC50 and IC90 of 20 nM and 200 nM for autotaxin in mouse plasma. PAT-048 reduces dermal fibrosis in vivo[1][2].

• UNSPSC:

  12352005

• Target:

  Phosphodiesterase (PDE)

• Type:

  Reference compound

• Related Pathways:

  Metabolic Enzyme/Protease

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/pat-048.html

• Solubility:

  10 mM in DMSO

• Smiles:

  CCCN1N=CC (N2C3=C (C (SC4=CC=CC (C (O) =O) =C4F) =C2C) C=CC (Cl) =C3F) =C1

• Molecular Formula:

  C22H18ClF2N3O2S

• Molecular Weight:

  461.91

• References & Citations:

  [1]Castelino FV, et al. An Autotaxin/Lysophosphatidic Acid/Interleukin-6 Amplification Loop Drives Scleroderma Fibrosis. Arthritis Rheumatol. 2016 Dec;68 (12) :2964-2974.|[2]Black KE, et al. Autotaxin activity increases locally following lung injury, but is not required for pulmonary lysophosphatidic acid production or fibrosis. FASEB J. 2016 Jun;30 (6) :2435-50.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  Autotaxin

• CAS Number:

  1359983-15-5